Cancer Advisor

Evidence review updated: September 2026 Bottom line: EnteroMix is a genuine experimental Russian cancer immunotherapy, but it is not an approved cancer cure and it is not the same thing as Russia's personalized mRNA cancer-vaccine programme. EnteroMix is an oncolytic virotherapy based on four enteroviruses . As of 2026, the publicly registered human evidence remains an early Phase I study focused primarily on safety, tolerability, pharmacokinetics and dose selection. Claims of "100% efficacy," dramatic tumour regression, or a proven cancer cure go substantially beyond the publicly verifiable clinical evidence. Important: EnteroMix should not be confused with Russia's separate personalized mRNA cancer-vaccine programme. The two technologies have different mechanisms, development programmes and evidentiary status. Contents 1. What is EnteroMix? 2. The critical correction: EnteroMix is not the mRNA vaccine 3. How EnteroMix is intended to work ...

This is a supplementary article that contain the case details, sources and references for the primary compilation article . Note: The case reports below offer detailed, practical information on fenbendazole, ivermectin, and cancer that clinicians can find both useful and actionable. Fenbendazole and Ivermectin Prostate Cancer Case Series Compilation and Presentations This compilation features several case reports from multiple sources involving the use of ivermectin and/or fenbendazole for prostate cancer. Tables 1 - 3 below provide a summary of the information for the cases presented in this paper, including therapies used, dosage, outcome, and prior treatments. The cases are organised into tables grouped by primary drug emphasis (FBZ-focused (Table 1), IVM-focused (Table 2), or combinations (Table 3)). Each table includes key details: case number, patient demographics, cancer details, protocol, outcomes, and notes. Due to volume, only high-detail cases are prioritized. For details o...